2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2137

Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Abstract Number: 2299

Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan：the First Report from the Pediatric Rheumatology Association of Japan (PRAJ)
Abstract Number: 1110

Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack
Abstract Number: 2730

Clinical Features and Treatment of Central Nervous System Vasculitis Associated with Acute Posterior Multifocal Placoid Pigment Epitheliopathy
Abstract Number: 2555

Clinical History of Psoriatic Arthritis over Four Decades
Abstract Number: 2661

Clinical Impact of Selenium and Vitamin C Deficiency in Systemic Sclerosis
Abstract Number: 1149

Clinical Implications of Ultrasonography (US) in Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparative Investigation By US between Auricle of RP, Repeated Trauma and Healthy Subject
Abstract Number: 1151

Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration
Abstract Number: 1280

Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University
Abstract Number: 215

Clinical Pharmacist As Part of the Interprofessional Team Improves Quality of Care in Patients with Rheumatic Disease
Abstract Number: 814

Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
Abstract Number: 2840

Clinical Presentation and Outcomes in Patients with Prosthetic Joint Septic Arthritis Who Had One-Stage Versus Two-Stage Joint Replacement
Abstract Number: 2082

Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study
Abstract Number: 560

Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Abstract Number: 1207

Clinical Relevance of Structural Measures in Knee Osteoarthritis: Baseline Values and Change from Baseline Discriminate Patients Subsequently Receiving Knee Replacement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].